Table 2 Sensitivity, specificity, PPV, NPV, and accuracy of serum FGF19 levels and the existing markers alone and in combination in all the HCC cases
From: Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) | |
|---|---|---|---|---|---|
Single marker | |||||
AFP | 44.4 | 96.5 | 96.4 | 44.8 | 61.0 |
DCP | 62.2 | 95.5 | 96.9 | 52.9 | 70.9 |
FGF19 | 53.2 | 95.1 | 95.9 | 48.7 | 66.6 |
Double markers | |||||
AFP and DCP | 73.7 | 91.7 | 95.3 | 61.0 | 77.6 |
AFP and FGF19 | 76.0 | 91.5 | 95.1 | 64.0 | 80.9 |
DCP and FGF19 | 81.3 | 91.0 | 95.4 | 68.8 | 82.5 |
Multiple markers | |||||
AFP, DCP, and FGF19 | 87.5 | 87.2 | 94.0 | 76.3 | 85.7 |